

*This press release constitutes a public disclosure of inside information by Neopharmed Gentili S.p.A. under Regulation (EU) 596/2014 and Commission Implementing Regulation (EU) 2016/1055.*

## **Neopharmed Gentili announces CEO transition**

**Milan, Italy – 18<sup>th</sup> July 2024** – Neopharmed Gentili S.p.A., a leading Italian primary care branded pharmaceutical company, backed by Ardian and NB Renaissance together with the Del Bono family, announces that CEO Eric Falcand has decided to step down from his position for personal reasons.

Over the last years, the company has seen significant growth, consolidating its position to become one of the top players in the Italian primary care market. The Board expresses its deep gratitude to Eric for his contributions since his appointment as CEO.

Alessandro Del Bono, who led the company prior to Eric's appointment and is the current Chairman of the Board, will continue leading the company until a new CEO is appointed by the Board of Directors.

"With regret, after a brief but intense collaboration, I greet Eric, to whom I express my esteem and gratitude for his work during these months, and I wish him a successful future. We'll continue to pursue our goals with the strength and determination that have always marked our history" said Alessandro Del Bono.

Eric Falcand also shared his thoughts on the transition: "It has been an intense few months of hard work since my arrival and I have met very talented people with whom I've had a lot of pleasure to interact with. I wish all the success the company deserves for the future."

[www.neogen.it](http://www.neogen.it)

### ***Forward Looking Statements***

*This press release may include "forward-looking statements" within the meaning of the securities laws of applicable jurisdictions. These forward-looking statements include, but are not limited to, all statements other than statements of historical facts contained in this press release, including, without limitation, those regarding Neopharmed Gentili's intentions, beliefs or current expectations concerning, among other things, its strategy, plans, objectives, prospects, growth, goals and targets. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "anticipate," "believe," "continue," "ongoing," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "seek" or, in each case, their negative, or other variations or comparable terminology. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future.*